CorPath GRX is a second generation robotic-assisted system built on the foundation of the CorPath 200’s clinical success with over 4,000 cases across more than 40 programs worldwide.
When using the CorPath System, studies have shown:*
The CORA-PCI Trial demonstrated 99.1% clinical success in complex cases along with comparable procedure times to manual PCI.1
The PRECISE trial demonstrated a 95% reduction in radiation exposure to the primary operator.2
A single center retrospective study published in the Journal of Invasive Cardiology demonstrated a 17% reduction in radiation dose to the patient compared to manual PCI.3
A recent study demonstrated that accurate measurement of coronary anatomy, using CorPath, reduced the use of unnecessary additional stents by 8.3%.4
1. Mahmud E, et al. Demonstration of the Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Coronary Lesions: Results of the Complex Robotically Assisted Percutaneous Coronary Intervention (CORA-PCI) Trial. Presented at SCAI 2016; Orlando, FL.
2. Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J American College of Cardiol, 2013, Vol 61, No. 15: 1596-1600.
3. Smilowitz N, et al. Robotic-Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol, 2014;26(7):318-321.
4. Campbell PT, et al. The Impact of Precise Robotic Lesion Length Measurement on Stent Length Selection: Ramification for stent savings. Cardiovasc Revasc Med. 2015;piii:S1553-8389.
* Includes studies conducted using CorPath 200
** Compared to the CorPath 200 System